Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients

Author:

Zaloumis Sophie G.1ORCID,Whyte Jason M.23,Tarning Joel45ORCID,Krishna Sanjeev6,McCaw James M.17,Cao Pengxing7,White Michael T.8,Dini Saber1ORCID,Fowkes Freya J. I.19,Maude Richard J.4510,Kremsner Peter1112,Dondorp Arjen45,Price Ric N.513,White Nicholas J.45,Simpson Julie A.1ORCID

Affiliation:

1. Centre for Epidemiology & Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia

2. Centre of Excellence for Biosecurity Risk Analysis, School of BioSciences, University of Melbourne, Melbourne, Australia

3. Australian Research Council Centre of Excellence for Mathematical and Statistical Frontiers, School of Mathematics and Statistics, University of Melbourne, Melbourne, Australia

4. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

5. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

6. Institute for Infection and Immunity, St. George’s Hospital, University of London, London, United Kingdom

7. School of Mathematics and Statistics, University of Melbourne, Melbourne, Australia

8. Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

9. Disease Elimination Program, Burnet Institute, Melbourne, Australia

10. Harvard TH Chan School of P`ublic Health, Harvard University, Boston, Massachusetts, USA

11. Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon

12. Gabon and Institut für Tropenmedizin, University of Tübingen, Tübingen, Germany

13. Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia

Abstract

Most deaths from severe falciparum malaria occur within 24 h of presentation to a hospital. Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria, but its efficacy may be compromised by delayed parasitological responses.

Funder

Wellcome Trust

Australian Research Council

Department of Health, Australian Government | National Health and Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference36 articles.

1. WHO. 2019. World malaria report 2019. WHO, Geneva, Switzerland.

2. Pathogenesis, clinical features, and neurological outcome of cerebral malaria

3. WHO. 2015. Guidelines for the treatment of malaria, 3rd ed. WHO, Geneva, Switzerland. https://www.afro.who.int/publications/guidelines-treatment-malaria-third-edition

4. WHO. 2016. Artemisinin and artemisinin-based combination therapy resistance. WHO, Geneva, Switzerland. https://apps.who.int/iris/handle/10665/250294

5. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3